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Abstract
Background: Normotensive non-diabetic relatives of type 1 diabetes (T1D) patients have an abnormal blood
pressure response to exercise testing that is associated with indices of metabolic syndrome and increased oxidative
stress. The primary aim of this study was to investigate the circadian variability of blood pressure and the
ambulatory arterial stiffness index (AASI) in healthy siblings of T1D patients vs healthy control subjects who had no
first-degree relative with T1D. Secondary aims of the study were to explore the influence of both cardiovascular
autonomic function and erythrocyte electron transfer activity as oxidative marker on the ambulatory blood pressure
profile.
Methods: Twenty-four hour ambulatory blood pressure monitoring (ABPM) was undertaken in 25 controls, 20 T1D
patients and 20 siblings. In addition to laboratory examination (including homeostasis model assessment of insulin
sensitivity) and clinical testing of autonomic function, we measured the rate of oxidant-induced erythrocyte
electron transfer to extracellular ferricyanide (RBC vfcy).
Results: Systolic blood pressure (SBP) midline-estimating statistic of rhythm and pulse pressure were higher in T1D
patients and correlated positively with diabetes duration and RBC vfcy; autonomic dysfunction was associated with
diastolic BP ecphasia and increased AASI. Siblings had higher BMI, lower insulin sensitivity, larger SBP amplitude,
and higher AASI than controls. Daytime SBP was positively, independently associated with BMI and RBC vfcy.
Among non-diabetic people, there was a significant correlation between AASI and fasting plasma glucose.
Conclusions: Siblings of T1D patients exhibited a cluster of sub-clinical metabolic abnormalities associated with
consensual perturbations in BP variability. Moreover, our findings support, in a clinical setting, the proposed role of
transplasma membrane electron transport systems in vascular pathobiology.
Background
So far, familial predisposition to arterial hypertension in
type 1 diabetes (T1D) families has been related to the
development of diabetic nephropathy and systemic
hypertension in the proband [1]. We have previously
shown that normotensive non-diabetic siblings of T1D
patients have abnormal blood pressure response to exer-
cise testing that is associated with indices of metabolic
syndrome and increased oxidative stress [2]. The pri-
mary aim of this study was to investigate the circadian
variability of blood pressure and the ambulatory arterial
stiffness index in healthy siblings of T1D patients vs
healthy control subjects who had no first-degree relative
with T1D. Secondary aims of the study were to explore
the influence of cardiovascular autonomic function and
erythrocyte electron transfer activity on the ambulatory
blood pressure profile. Human erythrocytes possess a
transplasma ferricyanide reductase activity (measured as
the erythrocyte velocity of ferricyanide reduction, RBC
vfcy) that transfers reducing equivalents from intracellu-
lar reductants to extracellular oxidants [3] and belongs
to the ubiquitous transplasma membrane electron trans-
port (TPMET) systems. TMET activities have been
related to the regulation of vital cellular processes and
to the pathogenesis of various human disorders [4] and
exist also in endothelial cells where they have been
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genesis through regulation of haeme oxygenase-1
expression [5].
Methods
Participants
We studied the following groups of subjects:
1) 20 T1D patients (12 women) with duration of disease
ranging from 1 to 47 years (23 ± 15 years). The group
included 8 patients with retinopathy (background or pro-
liferative, determined by fluorescein angiography following
fundus examination) and 1 patient with nephropathy
(persistent macroalbuminuria). None received medical
treatment except insulin (0.6 ± 0.2 IU/kg) and possibly
antihypertensive drugs (the patient with nephropathy was
taking angiotensin converting enzyme inhibitor and cal-
cium antagonist);
2) 20 normotensive non-diabetic siblings (12 women)
of T1D patients. None had clinical evidence of illness or
was taking any drugs;
3) 25 healthy subjects (16 women) were recruited
from the local community to achieve a similar distribu-
tion of age and sex to the families. They had no family
history of T1D, were taking no drugs, and had no clini-
cal signs or symptoms of illness.
All subjects gave informed consent and the ethical
committee of the hospital approved the study proposal.
The medical examination included standardised family
and personal medical history, physical examination,
blood chemistry analysis, tests for cardiovascular auto-
nomic functions, resting ECG, and 24-h ambulatory
blood pressure monitoring (ABPM).
Data collection
The family and personal medical history and the find-
ings of the clinical examination were recorded (body
mass index, blood pressure, and cigarette smoking
included). The body mass index (BMI) was calculated as
body weight/height
2 (in kg/m
2). After 10 minutes rest,
sitting systolic and diastolic blood pressure were mea-
sured twice. The mean was reported as office SBP and
DBP. Individuals not receiving any antihypertensive
drug therapy with resting (sitting) SBP/DBP less than
140/90 mmHg were placed in normal blood pressure
category.
Tests of autonomic function
Autonomic function was assessed using four standardised
autonomic function tests according to Ewing et al. [6]:
deep breathing, lying to standing, Valsalva manoeuvre,
and orthostatic hypotension. Heart rate variability (HRV)
was analysed using NeuroTester device (Me.Te.Da. srl,
San Benedetto del Tronto, Italy) and evaluated using age-
related reference values [7]. Expiration/inspiration ratio
at deep breathing (E:I), maximum/minimum ratio after
change in position (30:15), and Valsalva ratio were scored
as 0 (normal), 1 (borderline), or 2 (abnormal). Orthostatic
fall in SBP (Standing ΔSBP) was defined abnormal if > 20
mmHg. Patients with at least one abnormal or two bor-
derline cardiovascular tests (score ≥2) were considered to
have autonomic neuropathy [8].
Ambulatory blood pressure monitoring
The 24-h ABPM was performed using an automatic
oscillometric device (Takeda TM-2430) and data were
analysed using SIGMA 2000 software. Patients should
keep their habitual routine and present a report with
the activities done. SBP, DBP and heart rate (HR) were
recorded every 15 minutes throughout the day and
every 30 minutes at night. SBP, DBP, and HR measure-
ments were averaged for the day and the night spans
according to the patients’ reported time of waking up
and going to bed. The pulse pressure (PP) was calcu-
lated as the difference between the SBP and the DBP.
The normal dip was defined as a 10% or greater reduc-
tion in BP during sleep compared with the awake per-
iod. The circadian characteristics of BP were also
estimated: MESOR (midline-estimating statistic of
rhythm), amplitude (half of difference between highest
and lowest value of curve), and acrophase (timing of
highest value in curve). Ambulatory arterial stiffness
index (AASI) was computed from 24-h recordings of
each participant as 1 minus the regression slope of DBP
on SBP [9].
Laboratory methods
Fasting venous blood samples and morning urine sam-
ples were obtained on the same day just before starting
ABPM. Measurements were performed in freshly
obtained material immediately after withdrawal. Labora-
tory evaluation included fasting plasma glucose (FPG),
plasma creatinine and uric acid, HbA1c, blood cell
count, lipids (total, HDL, LDL cholesterol, and triglycer-
ides), bilirubin, liver enzymes, urinary glucose, albumin
and creatinine excretion. Urinary albumin-to-creatinine
ratio (ACR) was calculated by dividing the urinary albu-
min concentration in μg by the urinary creatinine mg.
Concentrations of fasting plasma insulin (FPI) were
measured by commercial radioimmunoassay (Medgenix
Diagnostics, Fleurus, Belgium). Homeostasis model
assessment of insulin sensitivity (HOMA-IS) was calcu-
lated as the product of the FPI and FPG divided by 22.5.
To measure RBC vfcy, 4 ml venous blood were drawn
into heparin tubes and immediately centrifuged at 54 g
for 9 min at 20°C to remove platelet-rich plasma. After
packed erythrocytes were washed three times in 10
volumes of phosphate-buffered saline, 0.5 ml of the-
packed cells were diluted to 5 ml with phosphate-
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incubated under magnetic stirring in a water bath at 37°
C. At 5, 10, 20 and 40 minutes 0.3 ml of cell suspension
were removed and centrifuged at 3110 g for 4 min at
4°C. An aliquot of 0.05 ml of the supernatant was
sampled, and the ferrocyanide content was measured
spectrophotometrically (from its absorbance at 535 nm
with 4,7-diphenyl-l,10-phenanthroline sulfonated as the
color-developing agent against a 0 time blank). The
initial rate of ferrocyanide generation was expressed
relative to the packed cell volume as micromoles per ml
packed RBCs per hour [3].
Statistical analyses
Analysis was performed using Aabel 3 (Gigawiz, Okla-
homa City, Oklahoma, USA). Results are given as mean
SD or median with range (Standing ΔSBP, triglycerides,
and ACR). Statistical comparison was by chi-square test,
the Student’s unpaired t test or the Mann-Whitney U-test
with Bonferroni correction for multiple hypothesis testing.
The cut-off level for statistical significance was set at p <
0.05. Pearson’s correlation coefficient or Spearman’sr h o
was computed to determine the correlation between vari-
ables. Multivariate regression analysis was used to deter-
mine independent predictors of the variables of interest;
candidate predictors selected in the multivariate model
were the variables significantly associated by simple uni-
variate correlation analysis.
Results
The clinical characteristics of the study groups are
reported in Table 1. T1D patients had higher office SBP
(duplicate measurements) than control subjects, but still
in the normal range. Their siblings showed slightly
higher BMI than control subjects, but similar office BP
levels.
While HR analysis under paced breathing did not evi-
dence any significant difference among groups, HRV in
response to standing and Valsalva manoeuvre was
abnormal in T1D patients. Five of them had an auto-
nomic neuropathy score ≥2.
From the biochemical viewpoint (Table 2), T1D
patients differed from both the control subjects and their
own siblings in the higher FPG and HbA1c (as expected)
as well as in the lower plasma levels of triglycerides; they
also had lower plasma LDL cholesterol than siblings. Sib-
lings differed from the control group in the higher FPG
but lower HbA1c. The range of FPG was from 4.0 to
5.8 mmol/l (FPI from 2.2 to 28.7 μU/ml) in control sub-
jects and from 4.4 to 6.1 (FPI from 6.3 to 42.3) in siblings.
HOMA-IS was significantly lower in siblings than the
control group (0.48 ± 0.20 vs 0.70 ± 0.43, p < 0.05).
ABPM confirmed the 24-h SBP, 24-h PP, nighttime
SBP and SBP MESOR to be significantly higher in T1D
patients (one T1D patient with recording duration of 20
hours, who declined further attempts, was excluded
from the correlation analysis) than in control subjects
and siblings (Table 3). In bivariate correlation analysis,
24-h PP correlated positively and significantly with the
duration of diabetes (r = 0.75, p < 0.001; Figure 1),
HbA1c (r = 0.64, p < 0.01), RBC vfcy (r = 0.59, p <
0.01), and autonomic neuropathy score (r = 0.46, p <
0.05). In multivariate analyses, duration of diabetes (b
coefficient = 0.45, p < 0.001) and RBC vfcy (b =1 . 7 0 ,
p = 0.01) resulted to be independently related to PP (r =
0.84, p < 0.001). Moreover, in T1D patients DBP acro-
phase occurred earlier (despite the same time of awa-
kening and in the absence of an oddly timed pattern of
HR) and was positively associated (r = 0.70) with HRV
in response to deep breathing after controlling for age
and diabetes duration (b = 19.52, p = 0.01, Figure 2).
Unlike office duplicate BP measurements, ABPM
records of siblings revealed the daytime SBP, daytime
DBP, and SBP amplitude to be higher than controls’
values. Among non-diabetic people in the study, daytime
SBP was associated positively with BMI (r = 0.55, p <
0.001), HbA1c (r = 0.36, p = 0.01), RBC vfcy (r = 0.34,
p < 0.05; Figure 3) and negatively with HOMA-IS (r =
Table 1 Clinical characteristics of the study participants
Characteristic Controls T1D patients Siblings
Age (years) 46 ± 12 46 ± 10 45 ± 10
BMI (kg/m
2) 2 4±3 2 5±4 2 6±5 *
Office SBP (mmHg) 117 ± 9 126 ± 14￿ 118 ± 21
Office DBP (mmHg) 79 ± 4 79 ± 9 82 ± 12
Never smoker/smoker/ex 14/6/5 11/4/5 13/2/5
Deep Breathing (E:I) 1.36 ± 0.14 1.33 ± 0.12 1.36 ± 0.17
Lying to Standing (30:15) 1.42 ± 0.39 1.20 ± 0.14* 1.45 ± 0.28‡
Valsalva ratio 2.07 ± 0.70 1.68 ± 0.33* 1.95 ± 0.46†
Standing ΔSBP [-5, -20 +10] [-10, -45 +10] [-8, -30 +10]
Data are mean ± SD or [median, range]. *p < 0.05, ￿p < 0.01, ¶p < 0.001 comparing T1D or their siblings vs. normal control subjects; †p<0 . 0 5 ,‡p < 0.01, #p <
0.001 comparing siblings vs. T1D.
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; Standing ΔΔSBP, orthostatic fall in SBP.
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sis, the relationship for BMI (b = 1.48, p < 0.001) and
RBC vfcy (b = 1.04, p < 0.01) with daytime SBP remained
(r = 0.61, p < 0.001).
Five control subjects, 6 T1D patients, and 1 sibling
had a non-dipping pattern of SBP on the ABPM; 4 con-
trol subjects, 7 T1D patients, and 1 sibling had a non-
dipping pattern of DBP. The total score for autonomic
neuropathy (the sum of the four test scores) accounts
for the major part of the non-dipping systolic (r = -0.58,
p < 0.01) and diastolic (r = -0.70, p < 0.001) profile in
the T1D patients.
AASI was higher in members of T1D families, pro-
bands and siblings, than in control subjects. In T1D
patients it was associated negatively with E:I ratio at
deep breathing (r = -0.67, p = 0.001) and positively with
age (r = 0.63, p < 0.01), duration of the disease (r =
0.53, p < 0.05), and HbA1c (r = 0.48, p < 0.05). On mul-
tivariate regression HRV during deep breathing
remained the independent predictor of AASI (b = -0.69,
p < 0.01) even when 24-h SBP was included in the
model. In the non-diabetic study groups there was a sig-
nificant positive relationship between AASI and FPG
(r = 0.29, p < 0.05).
Discussion
Ambulatory BP, particularly the circadian variability of
BP, may be a better predictor of cardiovascular disease
than office BP in the general population [10]. Abnormal
circadian BP patterns have been described in high-risk
T1D patients with diabetic nephropathy and/or auto-
nomic neuropathy [11,12]. Our T1D patients, 95% of
whom were normoalbuminuric, had higher 24-h PP
(due to higher MESOR, daytime and nighttime SBP)
whose variance was mainly accounted for disease dura-
tion, thus confirming recent observations [12]. Philips el
al. measured SBP and DBP continuously with a Finapres
(FINger Arterial PRESsure) device and found a progres-
sive PP increase in T1D patients according to disease
duration, especially after 20 years of diabetes, in an age
range (<50 years) where such a PP rise was not observed
in non-diabetic individuals. In our T1D patients, cardio-
vascular autonomic neuropathy was independently cor-
related with their higher AASI. Normoalbuminuric T1D
patients have been found to have increases in arterial
stiffness, which, in turn, were associated with, and could
cause, increased systolic and pulse pressure [13]. One of
the main mechanisms thought to be involved is the
formation of advanced glycation end products [14].
However, BP alterations are early occurrences in T1D
[15] and acute hyperglycaemia alone (120 min hypergly-
caemic clamp) is sufficient to increase the stiffness of
intermediate-sized arteries and resistance arteries in
Table 2 Biochemical characteristics of the study participants
Characteristic Controls T1D patients Siblings
FPG (mmol/l) 4.9 ± 0.4 10.5 ± 3.6¶ 5.2 ± 0.5*#
HbA1c (%) 5.3 ± 0.3 8.6 ± 1.4¶ 5.1 ± 0.3*#
Total cholesterol (mmol/l) 5.2 ± 0.7 4.9 ± 0.9 5.3 ± 1.0
HDL cholesterol (mmol/l) 1.5 ± 0.4 1.6 ± 0.3 1.4 ± 0.3
LDL cholesterol (mmol/l) 2.9 ± 0.6 2.8 ± 0.7 3.2 ± 0.9†
Triglycerides (mmol/l) [1.0, 0.4-1.7] [0.7, 0.4-1.2]° [0.8, 0.5-1.7]†
Plasma creatinine (μmol/l) 84 ± 13 93 ± 10* 87 ± 12
ACR (μg/mg) [3.2, 0-18] [2.5, 0-1395] [2.5, 0-12]
RBC vfcy (mmol/ml h) 10.1 ± 2.5 9.6 ± 2.6 10.4 ± 2.9
Data are mean ± SD or [median, range]. *p < 0.05, °p < 0.01, ¶p < 0.001 comparing T1D or their siblings vs. normal control subjects; †p < 0.05, ‡p<0 . 0 1 ,# p<
0.001 comparing siblings vs. T1D.
FPG, fasting plasma glucose; HDL, high density lipoprotein; LDL, low density lipoprotein; ACR, albumin-to-creatinine ratio; RBC vfcy, erythrocyte velocity of
ferricyanide reduction.
Table 3 Measures of ambulatory blood pressure
monitoring
Characteristic Controls T1D patients Siblings
24-h SBP (mmHg) 121 ± 7 135 ± 12¶ 127 ± 13†
24-h DBP (mmHg) 74 ± 4 77 ± 5 78 ± 8
24-h PP (mmHg) 46 ± 4 58 ± 11¶ 49 ± 8‡
AASI (units) 0.47 ± 0.13 0.62 ± 0.15# 0.56 ± 0.13*
Daytime SBP (mmHg) 125 ± 7 139 ± 12¶ 132 ± 14*
Daytime DBP (mmHg) 77 ± 4 79 ± 7 81 ± 8*
Nighttime SBP (mmHg) 107 ± 10 122 ± 17° 108 ± 15†
Nighttime DBP (mmHg) 65 ± 8 68 ± 7 66 ± 8
SBP Mesor (mmHg) 121 ± 6 135 ± 12¶ 127 ± 13†
SBP Amplitude (mmHg) 10 ± 5 12 ± 5 14 ± 6°
SBP Acrophase (h) 14 ± 3 14 ± 5 14 ± 2
DBP Mesor (mmHg) 75 ± 4 77 ± 5 78 ± 8
DBP Amplitude (mmHg) 7 ± 3 6 ± 4 8 ± 4
DBP Acrophase (h) 14 ± 3 11 ± 3° 14 ± 2#
Data are mean ± SD. *p < 0.05, °p < 0.01, ¶p < 0.001 comparing T1D or their
siblings vs. normal control subjects; †p < 0.05, ‡p < 0.01, #p < 0.001
comparing siblings vs. T1D.
PP, pulse pressure; AASI, ambulatory arterial stiffness index.
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well as in healthy subjects in a rather similar manner
[16]. Indices of cardiovascular autonomic neuropathy
also deteriorate with diabetes duration and shifts of the
sympathovagal balance might in part account for vascu-
lar dysfunction [11], as our data suggest.
T h ea c r o p h a s eo fD B P ,i . e .t h et i m eo ft h em a x i m u m
of the DBP, registered in T1D probands was 3 hours
earlier than normal and DBP ecphasia (altered circadian
timing) was more pronounced in patients with lower
HR variability during deep breathing. This is a novel
finding in type 1 diabetes, which is consistent with
Figure 1 Relationship between 24-h pulse pressure (mmHg) and duration of type 1 diabetes (years).
Figure 2 Linear regression plot of diastolic blood pressure (DBP) acrophase in type 1 diabetic patients vs. heart rate variability in
response to deep breathing, expressed as expiration/inspiration ratio (E:I).
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[17]. Changes in the time structures of melatonin and
BP have been described in diabetes and associated with
autonomic nervous dysfunction [18]. Recent results
prove that streptozotocin-induced T1D increases the
plasma melatonin level and confirm a melatonin-insulin
antagonism [19]. In T1D, despite sophisticated regimens
of subcutaneous insulin substitution, the elevated levels
of circulating insulin could impact on the circadian reg-
ulation of BP by melatonin.
Among previous investigations focused on the rela-
tionship between familial predisposition to hypertension
and diabetic nephropathy, only one monitored 24-h
ambulatory BP in adult T1D relatives (parents aged
Figure 3 Linear regression plots of daytime systolic blood pressure (SBP, mmHg) in siblings vs. BMI (upper panel) and erythrocyte
transplasma membrane electron transport, RBC vfcy as micromoles of ferrocyanide generated per milliliter packed RBCs per h (lower
panel).
Matteucci et al. Cardiovascular Diabetology 2010, 9:61
http://www.cardiab.com/content/9/1/61
Page 6 of 9about 67 years) [1]. The present study is first to evaluate
24-h ambulatory BP in healthy siblings of similar adult
age as the (mostly uncomplicated) probands. Siblings
differed from control subjects in the following respects:
higher BMI and FPG, lower HbA1c and HOMA-IS,
abnormal diurnal profiles of SBP at ABPM, and abnor-
mal dynamic relationship between SBP and DBP over
24 h as described by AASI.
Originally, the presence of insulin resistance was high-
lighted in family members of T1D patients with microal-
buminuria [20]. Currently, the accelerator hypothesis
proposes that type 1 and type 2 diabetes are both driven
by insulin resistance [21]. In the course of our studies
on non-diabetic first-degree T1D relatives [2,22], we
ourselves have repeatedly documented the tendency
towards a similar metabolic derangement. In the present
study, siblings had FPG slightly higher than control sub-
jects yet lower HbA1c levels. According to the 2003
ADA definition, 6 siblings (vs 2 control subjects) had
impaired fasting glucose (IFG). Having FPG < 7.0
mmol/l and HbA1c < 6.0%, our siblings presumably did
not require an oral glucose tolerance test to exclude dia-
betes [23]. Five-year follow-up data from the Inter99
study evidenced that the proportion of individuals with
a family history of diabetes was highest in the groups
who later developed IFG and IFG/IGT (impaired glu-
cose tolerance). The pre-diabetic state, IFG, was charac-
terised by a baseline stationary reduced insulin secretion
in combination with a progressive decline in HOMA-IS,
assumed to reflect hepatic insulin sensitivity [24]. The
combination of higher mean FPG, lower HOMA-IS and
lower HbA1c levels suggested that siblings with isolated
IFG (thus impaired basal glucose clearance rate) may
also have lower postprandial glycaemia values (due to
enhanced insulin-stimulated muscle glucose disposal)
[25]. Recently, 7-day ABPM uncovered that prediabetics
had higher incidence of high mean BP, excessive PP
and/or circadian hyper-amplitude-tension (a circadian
BP amplitude above the upper 95% prediction limit of
healthy peers matched by gender and age) [26]. Simi-
larly, our siblings reached higher values of daytime SBP
and SBP amplitude than controls.
A circadian hyper-amplitude-tension (based on a chron-
obiological classification) has been associated with an
increased risk of cardiovascular diseases such as stroke,
coronary artery disease, nephropathy, and retinopathy
[27]. Longitudinal studies in animal models of hyperten-
sion have reported that an increase in the circadian ampli-
tude of BP precedes a rise in the circadian BP average or
MESOR hypertension [28]. Thus, in accordance with
scientific evidence, these siblings seem to be in a predia-
betes and prehypertension phase. In nondiabetic, normo-
tensive participants in the San Antonio Heart Study,
subjects with prehypertension were at increased risk of
diabetes and much of this risk was accounted for disorders
related to the insulin resistance syndrome [29]. Plasma
glucose level is likely to be a continuous cardiovascular
risk factor even within a range that is below the diabetic
threshold. In hypertensive patients with type 2 diabetes,
nocturnal systolic blood pressure and hyperglycemia were
co-factors for an increased prevalence of left ventricular
hypertrophy [30]. Nevertheless, in our multivariate model,
siblings’ mean daytime SBP was independently related
only to BMI and RBC vfcy. Indeed, even a mild increase of
BMI increased the risk of prehypertension [31], as found
here. Familiarity for type 2 diabetes showed some influ-
ence on autonomic nervous system. A global reduction
and alteration of circadian rhythm of autonomic activity
(evaluated by HRV with 24-hours ECG Holter registra-
tion) were present in nondiabetic offspring of type 2 dia-
betic patients [32]. In our study, however, tests of
autonomic function were normal in siblings.
Present true novelty lies in that the daytime SBP, as
well as PP, is partly explained by RBC vfcy. All eukaryo-
tic cells possess TMET systems that transfer electrons
across the plasma membrane; the reduction of extracel-
lular oxidants takes place at expense of intracellular
reductants (NADH, NADPH, ascorbate, glutathione,
etc.). TMET capacity has been related to various cellular
functions: growth, proliferation, differentiation, apopto-
sis, bioenergetics, cell signal transduction, antioxidation,
and iron/copper metabolism [4]. Consequently, TPMET
dysfunction has been implied in various human patholo-
gies, diabetes included [3], even though the molecular
structures responsible for the trans-plasma membrane
transfer remain incompletely identified. Suggested
mechanisms of this transfer are probably twofold: 1)
enzyme-mediated electron transfer through the redox
centers of plasma membrane oxidoreductases, and 2)
transmembrane metabolite shuttling/cycling (particularly
ascorbate/dehydroascorbate cycling by plasma mem-
brane conduits and/or exocytosis) [4]. The complex
relationship between body mass and electron pathways
through erythrocyte plasma membrane has already been
addressed [33]. Endothelial cells also possess TPMET
systems that transfer intracellular reducing equivalents
to blood-borne electron acceptor and whose activity is
modulated by cytoplasmic redox status [34] as well as
by extracellular molecules such as homocysteine [35]. In
endothelium-denuded bovine pulmonary arteries,
increasing haeme oxygenase 1 activity is associated with
an attenuation of pulmonary artery relaxation and solu-
ble guanylate cyclase activation responses to nitric oxide
[36]. Increased haeme oxygenase 1 activity could attenu-
ate relaxation to nitric oxide through depleting the
haeme of soluble guanylate cyclase, which controls its
cyclic guanosine monophosphate generating activity.
Since TPMET activity is highly correlated with the
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and with the expression of haeme oxygenase 1 [5], the
vasoactive actions of this enzymatic activity may partly
contribute to the observed relation between BP and
RBC vfcy.
AASI, recently suggested as a marker of arterial stiff-
ness, resulted to be significantly heritable both before
and after adjustment for classical covariates [37]. In our
(albeit small) sample of non-diabetic people, on the con-
trary, AASI was correlated with a metabolic variable such
as plasma glycaemia. However, it should be noticed that
our sample is older than Swedish healthy siblings.
Evidence on this regard suggest that: 1) in diabetic rats,
elastic properties of the aorta are impaired, being closely
related to hyperglycemia-induced vascular wall remodel-
ling [38], 2) in a substudy of the Finnish population-
based Health 2000 Survey, FPG levels were independently
associated with increased arterial stiffness [39], 3) over a
3-year period in 2080 Japanese men BP and FPG levels
even below those defining hypertension and diabetes
mellitus, respectively, could synergistically lead to pro-
gression of arterial stiffening [40].
In conclusion, non-diabetic siblings of T1D patients
show signs of reduced insulin sensitivity, larger circadian
amplitude of SBP and higher ambulatory arterial stiff-
ness index. Their broader range of BMI and FPG
(increasing from low-normal FPG to IFG) portends nas-
cent or established glucoregulatory perturbations and is
associated with consensual perturbations in vascular
homeostasis. Moreover, our findings support the pro-
posed role of TPMET systems in vascular pathobiology,
which deserves further clinical investigations.
Limitations
We are aware that repeated ABPM recordings could be
recommended to correctly estimate the consistency of
BP abnormalities and diagnose circadian hyper-ampli-
tude-tension [26]. However, the use of a single ABPM is
common in literature also in consideration of the cost/
benefit ratio. General recommendations (2007 ESH-ESC
arterial hypertension guidelines) suggest the use of the
ABPM when clinic BP shows unusual variability and
when symptoms suggest the possibility of hypertension,
which is not the case for our siblings and controls at
baseline. Obtaining another ABPM is advisable if the
first examination has less than 70% of the expected
number of valid values because of artefacts.
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